Fort Worth biotech company Eyevance Pharmaceuticals acquired in $225M deal

There’s another exit in the North Texas startup scene that further points to the increased interest the biotech industry has seen during the pandemic. Santen Holdings U.S., a subsidiary of Japan’s Santen Pharmaceuticals announced an agreement to acquire Fort Worth-based Eyevance Pharmaceuticals, a biotech startup focused on developing and commercializing topic ophthalmic products. “We are excited to become part of Santen’s U.S. organization, to work in collaboration to further strengthen…